Your browser doesn't support javascript.
loading
Preclinical Characterization and Phase I Study of an Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies.
Janku, Filip; Han, Sae-Won; Doi, Toshihiko; Amatu, Alessio; Ajani, Jaffer A; Kuboki, Yasutoshi; Cortez, Alex; Cellitti, Susan E; Mahling, Ping C; Subramanian, Kulandayan; Schoenfeld, Heidi A; Choi, Sarah M; Iaconis, Lori A; Lee, Lang Ho; Pelletier, Marc R; Dranoff, Glenn; Askoxylakis, Vasileios; Siena, Salvatore.
Affiliation
  • Janku F; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Han SW; Department of Internal Medicine, Seoul National University Hospital and Seoul National University Cancer Research Institute, Seoul, Republic of Korea.
  • Doi T; National Cancer Center Hospital East, Chiba, Japan.
  • Amatu A; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  • Ajani JA; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kuboki Y; National Cancer Center Hospital East, Chiba, Japan.
  • Cortez A; Novartis Institutes for BioMedical Research, San Diego, California.
  • Cellitti SE; Novartis Institutes for BioMedical Research, San Diego, California.
  • Mahling PC; Novartis Pharma AG, Basel, Switzerland.
  • Subramanian K; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Schoenfeld HA; Novartis Institutes for BioMedical Research, East Hanover, New Jersey.
  • Choi SM; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Iaconis LA; Novartis Institutes for BioMedical Research, San Diego, California.
  • Lee LH; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Pelletier MR; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Dranoff G; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Askoxylakis V; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Siena S; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Cancer Immunol Res ; 10(12): 1441-1461, 2022 12 02.
Article in En | MEDLINE | ID: mdl-36129967
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunoconjugates / Antineoplastic Agents, Immunological / Neoplasms / Antineoplastic Agents Type of study: Clinical_trials Limits: Humans Language: En Journal: Cancer Immunol Res Year: 2022 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunoconjugates / Antineoplastic Agents, Immunological / Neoplasms / Antineoplastic Agents Type of study: Clinical_trials Limits: Humans Language: En Journal: Cancer Immunol Res Year: 2022 Document type: Article Country of publication: